ERIS Lifesciences Ltd

ERIS Lifescience Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

ERIS Lifesciences Ltd

₹ 1,023 -0.68%
28 Jun - close price
eris.co.in BSE: 540596 NSE: ERIS
About

ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]

Key Points

Product Offerings
The company offers 350+ pharmaceutical products/ formulations in the Indian pharmaceutical market.[1] It is a pure-play domestic branded formulations company with no export presence.[2]

Website BSE NSE
  • Market Cap ₹ 13,924 Cr.
  • Current Price ₹ 1,023
  • High / Low ₹ 1,067 / 683
  • Stock P/E 46.5
  • Book Value ₹ 186
  • Dividend Yield 0.72 %
  • ROCE 10.1 %
  • ROE 12.6 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • The company has delivered a poor sales growth of 10.6% over past five years.
  • Tax rate seems low

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
257 306 323 305 282 329 355 332 315 411 410 324 341
163 184 186 182 181 203 214 206 203 256 265 250 262
Operating Profit 94 123 137 123 102 126 141 126 111 156 144 74 79
OPM % 37% 40% 42% 40% 36% 38% 40% 38% 35% 38% 35% 23% 23%
3 6 8 6 9 3 6 3 4 4 7 3 20
Interest 0 0 1 1 1 7 7 3 3 7 7 15 29
Depreciation 10 11 12 14 15 15 16 16 17 20 25 28 29
Profit before tax 86 117 132 114 95 107 124 110 96 133 120 35 42
Tax % 20% 9% 10% 9% 8% 11% 7% 10% 8% 16% 2% 9% 5%
69 107 120 104 87 96 115 99 88 111 118 32 40
EPS in Rs 5.11 7.86 8.81 7.66 6.38 7.03 8.47 7.31 6.46 8.14 8.66 2.33 2.90
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
417 520 548 605 713 761 897 1,020 1,109 1,216 1,331 1,487
325 436 437 435 442 445 562 661 691 727 825 1,033
Operating Profit 92 84 111 171 271 316 334 359 417 488 506 454
OPM % 22% 16% 20% 28% 38% 42% 37% 35% 38% 40% 38% 31%
1 9 7 3 25 28 32 11 10 25 16 35
Interest 0 0 0 0 1 10 23 2 1 3 21 57
Depreciation 2 4 15 20 21 22 32 45 38 51 65 102
Profit before tax 90 89 103 154 274 312 312 324 389 459 437 329
Tax % 27% 27% 19% 10% 9% 6% 8% 10% 10% 9% 9% 9%
66 65 83 138 248 294 285 291 351 417 398 300
EPS in Rs 4,785.45 4,738.18 6,060.36 10,034.18 18.05 21.36 20.75 21.45 25.82 30.69 29.27 22.03
Dividend Payout % 0% 0% 0% 61% 0% 0% 0% 13% 21% 20% 25% 0%
Compounded Sales Growth
10 Years: 11%
5 Years: 11%
3 Years: 10%
TTM: 12%
Compounded Profit Growth
10 Years: 17%
5 Years: 1%
3 Years: -5%
TTM: -24%
Stock Price CAGR
10 Years: %
5 Years: 15%
3 Years: 10%
1 Year: 46%
Return on Equity
10 Years: 24%
5 Years: 20%
3 Years: 18%
Last Year: 13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 0 0 0 0 14 14 14 14 14 14 14 14
Reserves 119 184 267 305 561 854 1,142 1,286 1,562 1,905 2,208 2,510
0 0 1 0 0 376 176 0 0 0 317 2,572
55 83 86 96 82 126 138 183 179 232 245 254
Total Liabilities 174 268 354 402 657 1,370 1,470 1,483 1,755 2,150 2,784 5,350
15 64 61 65 92 490 484 601 584 642 898 1,516
CWIP 0 0 0 0 0 0 3 4 2 3 0 0
Investments 58 98 182 206 381 546 580 320 531 778 997 1,619
101 106 110 131 184 335 403 558 638 728 889 2,214
Total Assets 174 268 354 402 657 1,370 1,470 1,483 1,755 2,150 2,784 5,350

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
40 90 92 133 210 236 216 265 395 369 322 336
-41 -85 -94 -45 -199 -593 2 127 -348 -268 -513 -2,492
-1 -0 1 -84 -18 363 -221 -334 -81 -88 194 2,160
Net Cash Flow -1 5 -1 4 -6 7 -2 58 -34 13 3 4

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 15 16 16 15 21 29 31 50 37 41 63 59
Inventory Days 193 130 181 156 161 194 206 145 119 155 98 119
Days Payable 71 93 121 88 86 266 207 200 159 177 128 181
Cash Conversion Cycle 137 52 75 84 97 -43 30 -4 -3 19 33 -3
Working Capital Days 40 11 13 8 31 2 -22 58 65 80 82 91
ROCE % 105% 56% 44% 53% 62% 35% 26% 24% 27% 27% 20%

Shareholding Pattern

Numbers in percentages

2 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
52.69% 52.68% 52.66% 52.66% 52.30% 52.29% 52.70% 52.86% 52.86% 54.91% 54.90% 54.90%
13.49% 13.60% 13.34% 13.31% 15.35% 15.39% 15.50% 14.86% 13.78% 13.20% 13.13% 14.27%
10.05% 9.94% 10.37% 10.50% 10.66% 10.69% 9.95% 10.02% 10.73% 14.52% 14.55% 15.63%
23.77% 23.78% 23.62% 23.52% 21.69% 21.63% 21.85% 22.27% 22.63% 17.37% 17.41% 15.20%
No. of Shareholders 46,47749,83354,22357,06151,63948,05546,74645,93144,16942,24546,49651,753

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls